For anti-CD19 CAR-T cell therapy, a major difference between ALL and B-NHL is that the latter, like a solid tumor, has a microenvironment that can suppress T cell infiltration and activation 6. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.